Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2017 | LAG-3 antibody combination in immunotherapy-treated melanoma

Paolo Ascierto, MD, from Istituto Nazionale Tumori, Napoli, Italy, discusses the positive outcomes from a Phase I trial involving the treatment of patients with melanoma with an anti-lymphocyte activation gene-3 (LAG-3) antibody, BMS-986016, as well as anti-PD1/PD-1 therapy (NCT01968109). He reports a good safety profile and progression of disease in treated patients and believes that this combination may be promising in the future as it is the first regimen that can overcome treatment resistance in melanoma patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.